Bacteriophage therapy - cooked goose or Phoenix rising?

Michael Mattey*, Janice Spencer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)


Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.

Original languageEnglish
Pages (from-to)608-612
Number of pages5
JournalCurrent Opinion in Biotechnology
Issue number6
Early online date5 Nov 2008
Publication statusPublished - Dec 2008


  • bacteriophage therapy
  • bacterial diseases
  • human trials
  • animal trials

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering


Dive into the research topics of 'Bacteriophage therapy - cooked goose or Phoenix rising?'. Together they form a unique fingerprint.

Cite this